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Introduction
The NO-sGC-cGMP signaling pathway is impaired in
different cardiovascular diseases, including pulmonary
hypertension (PH). Riociguat is the first of a new class of
drugs, the soluble guanylate cyclase stimulators. Rioci-
guat has a dual mode of action: it sensitizes sGC to the
body’s own NO and can also increase sGC activity in the
absence of NO, causing vasorelaxation, anti-proliferation
and anti-fibrotic effects.
The aim of the study was to investigate the effects of
riociguat as compared to the PDE5 inhibitor sildenafil on
pulmonary vascular remodeling in severe experimental
PH.
Methods
Angioproliferative PH was induced in rats by combined
exposure to the vascular endothelial growth factor-
receptor antagonist SU5416 and hypoxia at 10%O2 (SU
+HOX). Twenty-one days thereafter, rats were rando-
mized for treatment with riociguat (10 mg/kg), sildenafil
(50 mg/kg) or vehicle for the next 14 days. Echocardio-
graphy and invasive hemodynamic measurements were
performed. Pulmonary vascular remodeling was assessed
by histomorphometric analysis.
Results
In rats with established PH, right ventricular systolic
pressure (RVSP) was significantly decreased by treat-
ment with riociguat to 73±4 mmHg (p<0.01) and silde-
nafil to 80±3 mmHg (p<0.05) as compared to placebo
(89±3 mmHg). No significant difference in systemic
arterial pressure was detected between placebo and trea-
ted animals. Both compounds significantly decreased RV
hypertrophy and improved RV function by normaliza-
tion of TAPSE and myocardial performance index, but
effects of riociguat were more pronounced. Riociguat
significantly reduced the proportion of occluded arteries
and increased proportion of opened arteries and
decreased neointima/media ratio.
Conclusion
We demonstrated that riociguat effectively suppresses pul-
monary vascular remodeling and significantly improves
RV function in an experimental model of severe PH.
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